Table 2.

Summary Results of the NNT and NNH analyses for patients receiving UPA vs VEDO, UST, or TOFA among the ITT population

AE adverse event, ITT intention-to-treat, N/A not applicable, NNH number needed to harm, NNT number needed to treat, SAE serious adverse event, UPA upadacitinib, UST ustekinumab, TOFA tofacitinib, VEDO vedolizumab

^aNNT defined as the inverse of the difference in proportions achieving efficacy outcomes where positive (negative) NNTs denote greater (lower) efficacy of UPA vs UST

^bNNH defined as the inverse of the difference in proportions achieving safety outcomes where positive (negative) NNHs denote greater (lower) safety risk of UPA vs UST

^cData were not available in the VEDO GEMINI-1 maintenance phase 3 trial. P value equals *p<0.05, **p≤0.01, ***p<0.001